Icl 2Million IU Injection contains Colistimethate Sodium equivalent to 2 million international units (IU) and is indicated for the treatment of serious infections caused by multidrug-resistant Gram-negative bacteria, including Pseudomonas aeruginosa and Acinetobacter species. Colistimethate Sodium is a polymyxin antibiotic that acts by disrupting the bacterial cell membrane, leading to cell death. This injectable formulation is primarily used in hospital settings for severe infections such as ventilator-associated pneumonia, bloodstream infections, urinary tract infections, and complicated intra-abdominal infections when alternative therapies are ineffective or contraindicated. The dosage and duration of therapy should be individualized based on the severity of infection, renal function, and patient response. Caution is advised in patients with pre-existing renal impairment due to the potential nephrotoxic effects of colistin. Monitoring of renal function and serum drug levels is recommended during treatment. Adverse effects may include nephrotoxicity, neurotoxicity, and hypersensitivity reactions. Icl 2Million IU Injection should be administered under strict medical supervision, and appropriate microbiological testing should guide therapy to ensure efficacy and minimize resistance development. This product is intended for intravenous or intramuscular use only and must be reconstituted according to manufacturer instructions prior to administration.